BOTHELL, Wash.--(BUSINESS WIRE)--Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced the launch of its ENVISION Clarity Trial, a Phase 2 clinical trial of ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD). ACU-4429 is one of the only treatments in development that works to slow the eye’s visual cycle for processing light. By slowing this cycle, ACU-4429 has demonstrated the ability to decrease the levels of toxic by-products in the eye and thereby potentially stop the advance of dry AMD. Dry AMD is a leading cause of vision loss in people over the age of 50, yet there are no therapies currently approved to treat this condition.
